BEFORE YOU READ ANYTING ELSE ABOUT THIS AMAZING COMPANY PLEASE READ PROPHETABLES STICKY BELOW***
$15 million dollar cash infusion by secret health care investor. Investors kept buying at .26 average, spending half there salary buying shares on the open market. Multi Dollars double digit dollars and triple digit dollars in the horizon. Anything under .10 is a gift.
1. Pre-Clinical Studies To Be Completed 2nd Q 2017
2. Application for IND Orphan Drug Status for its Cytotronics Product
3. Over 20 Patent Applications OWNED by the CEO and the Company
4. 10 Form 4s filed since Dec 2016 for Insider purchases of stock
5. A "Strategic Healthcare" Institutional Investor has Ponied up $15 mil to buy back Converts
6. Company paying off the rest of its debt with $2.2 million
7. Uplistment to a "National" exchange being considered
8. Has won their injunction against Kodiak Capital and other Financiers for diluting the stock
Endonovo Evaluating Therapeutic Potential of Non-Invasive Electroceutical Device Following Myocardial Infarction
Electromagnetic pulses are responsible for many of the activities in our bodies. They are an integral part of what keeps our hearts beating and brains functioning.
The bioelectronics device is a portable Time-Varying Electromagnetic Field (TVEMF) system. The unit uses a sophisticated miniaturized circuit board that delivers the specifically designed and patented electromagnetic field to a designated area of the body through the use of antennas (coils).
TVEMF> ENDV Patented Tech) vs PEMF> ALL Others)
Time-Varying Electromagnetic Field (TVEMF) technology is fundamentally different from other magnetic pulse devices. TVEMF is based on the physics of electricity and magnetism as well as the physiology of cells and tissues.
PEMF devices do not produce square waves, the optimal waveform for a tissue response.
PEMF devices do not produce enough intensity to stimulate a response; most do not even produce 1 Gauss of intensity.
PEMF devices do not produce a rate of induction (slew rate) that is quick enough to penetrate deep within tissues. TVEMF produces pulses that are only 0.0001 seconds wide.
Furthermore, TVEMF features repeating patterns of pulses that are selected based on known motor-neuron stimulation patterns of musculoskeletal tissues.
Why Square Waves?
Sine waves take too long to reach their peak intensity. The lower slew rate means that they are not effective in producing a cellular/tissue response.
Triangle and sawtooth waves also suffer from a lower slew rate, meaning that they are not effective in producing a cellular/tissue response.
Endonovo’s TVEMF device produces a patented square waveform, which was proven the most effective waveform to increase cell growth and the production of over 200 growth factors and cytokines.
Cytotronics™ Platform
Our Cytotronics™ platform uses Time-Varying Electromagnetic Field (TVEMF) technology to expand and enhance the therapeutic properties of stem cells, immune cells and for use in tissue engineering. The goal of our Cytotronics™ platform is to create optimized cell-based therapies with greater therapeutic potential than the un-modulated cells currently being used in regenerative medicine.
The origins of our Cytotronics™ platform dates back to experiments conducted at NASA to expand stem cells ex vivo and to create therapies that could be used to treat astronauts during long term space exploration. The results of those experiments revealed that Time-Varying Electromagnetic Fields (TVEMF) could be used to expand stem cells in the lab and resulted in the increased expression of dozens of genes related to cell growth, tumor suppression, cell adhesion and extracellular matrix production.
A Physics Approach to Biology – Ex Vivo Modulation
We have built upon over 15 years of research and development to create a novel therapeutic paradigm – the systematic enhancement of the biological and therapeutic properties of cells ex vivo. This allows for the creation of a precise, scalable and cost effective approach to maximize the safety and effectiveness of cell-based therapies.
While our competitors are using genetic modification and pharmacological modulation to alter and enhance the biological properties of cells, we are taking A Physics Approach to Biology™ in the use of bioelectronics to create ex vivo modulated cells with enhanced biological and therapeutic properties. Using our Cytotronics™ platform, we are able to create cells that express higher levels of key genes related to stem cell maintenance, cell growth, cell homing and engraftment. Cytotronic™ expansion of peripheral blood stem cells resulted in an over 80-fold expansion of CD34+ cells in as few as 6 days.
Our Cytotronic™ platform was shown to be able to maintain normal human neural progenitor (NHNP) cells in long term culture (180 days), undifferentiated with the ability to be cryogenically preserved then subsequently reintroduced into culture with stem and progenitor markers still intact. NHNP cells that were expanded using our technology were then shown to not be tumorigenic when introduced into nude (athymic) mice for 85 days. Multi-color Fluorescence In Situ Hybridization (mFISH) showed that there was no chromosomal damage to cells subjected to Time-Varying Electromagnetic Fields (TVEMF).
Perivascular Cell Therapy Created Using Cytotronics™
Each year, an estimated 60,000 patients with leukemia and lymphoma need bone marrow transplantation. However, only 25,000 of those patients actually receive a transplant, primarily because the other 35,000 patients are unable to find a fully matched bone marrow donor.
Umbilical cord blood from newborn children is an excellent source of hematopoietic stem cells for stem cell transplants because their immune system is still immature and the stem cells have a lower probability of inducing an adverse immune response in patients. Furthermore, a perfect immunological match between donor and recipient is not necessary, unlike in bone marrow transplants.
However, in most cases a unit of umbilical cord blood contains too few stem cells to treat an adult patient and its use is confined above all to the treatment of children. Numerous patients have better matched cord blood products available (5/6 or 6/6 HLA match), however those products have low cell doses and are not suitable for use in adult patients. This is one of the reasons why less than 3 percent of cord blood collected in the United States is ever used. Low volume cord blood units present the opportunity to expand and/or enhance these unused cord blood units for the widespread use of hematopoietic stem cells in regenerative medicine.
Off-The-Shelf Therapeutic
Our Perivascular Cell Therapy is created using immunologically privileged and immune-modulating stem cells from a portion of the human umbilical cord and co-cultured with adipose-derived stem cells along with cord blood cells to create a perivascular cell mixture that can be used to treat malignant and non-malignant hematological disorders.
Endonovo’s cell therapy is an off-the-shelf therapeutic that can be stored indefinitely in a low temperature freeze without requiring cryopreservation. Our technologies are particularly suited to expand the use and effectiveness of low-volume cord blood units.
More In Vivo-Like Stem Cells
Our off-the-shelf therapeutic is created in a three-dimensional bioreactor using our proprietary Cytotronics™ platform to further expand and enhance the biological properties of the stem cells within the perivascular cell mixture. Our use of a perivascular co-culture in a three-dimensional bioreactor is meant to mimic the way that blood-forming stem cells renew and reside in the body. This simulated stem cell niche allows for the expansion of long-term self-renewing stem cells. Researchers had previously identified endothelial and perivascular cells as the cells that were functionally responsible for the maintenance of blood-forming stem cells (HSCs) in the body. Our technologies provide a method for the expansion of HSCs in an environment that resembles their native stem cell niche..
$15 million dollar cash infusion by secret health care investor. Investors kept buying at .26 average, spending half there salary buying shares on the open market. Multi Dollars double digit dollars and triple digit dollars in the horizon. Anything under .10 is a gift.
1. Pre-Clinical Studies To Be Completed 2nd Q 2017
2. Application for IND Orphan Drug Status for its Cytotronics Product
3. Over 20 Patent Applications OWNED by the CEO and the Company
4. 10 Form 4s filed since Dec 2016 for Insider purchases of stock
5. A "Strategic Healthcare" Institutional Investor has Ponied up $15 mil to buy back Converts
6. Company paying off the rest of its debt with $2.2 million
7. Uplistment to a "National" exchange being considered
8. Has won their injunction against Kodiak Capital and other Financiers for diluting the stock
Endonovo Evaluating Therapeutic Potential of Non-Invasive Electroceutical Device Following Myocardial Infarction
Electromagnetic pulses are responsible for many of the activities in our bodies. They are an integral part of what keeps our hearts beating and brains functioning.
The bioelectronics device is a portable Time-Varying Electromagnetic Field (TVEMF) system. The unit uses a sophisticated miniaturized circuit board that delivers the specifically designed and patented electromagnetic field to a designated area of the body through the use of antennas (coils).
TVEMF> ENDV Patented Tech) vs PEMF> ALL Others)
Time-Varying Electromagnetic Field (TVEMF) technology is fundamentally different from other magnetic pulse devices. TVEMF is based on the physics of electricity and magnetism as well as the physiology of cells and tissues.
PEMF devices do not produce square waves, the optimal waveform for a tissue response.
PEMF devices do not produce enough intensity to stimulate a response; most do not even produce 1 Gauss of intensity.
PEMF devices do not produce a rate of induction (slew rate) that is quick enough to penetrate deep within tissues. TVEMF produces pulses that are only 0.0001 seconds wide.
Furthermore, TVEMF features repeating patterns of pulses that are selected based on known motor-neuron stimulation patterns of musculoskeletal tissues.
Why Square Waves?
Sine waves take too long to reach their peak intensity. The lower slew rate means that they are not effective in producing a cellular/tissue response.
Triangle and sawtooth waves also suffer from a lower slew rate, meaning that they are not effective in producing a cellular/tissue response.
Endonovo’s TVEMF device produces a patented square waveform, which was proven the most effective waveform to increase cell growth and the production of over 200 growth factors and cytokines.
Cytotronics™ Platform
Our Cytotronics™ platform uses Time-Varying Electromagnetic Field (TVEMF) technology to expand and enhance the therapeutic properties of stem cells, immune cells and for use in tissue engineering. The goal of our Cytotronics™ platform is to create optimized cell-based therapies with greater therapeutic potential than the un-modulated cells currently being used in regenerative medicine.
The origins of our Cytotronics™ platform dates back to experiments conducted at NASA to expand stem cells ex vivo and to create therapies that could be used to treat astronauts during long term space exploration. The results of those experiments revealed that Time-Varying Electromagnetic Fields (TVEMF) could be used to expand stem cells in the lab and resulted in the increased expression of dozens of genes related to cell growth, tumor suppression, cell adhesion and extracellular matrix production.
A Physics Approach to Biology – Ex Vivo Modulation
We have built upon over 15 years of research and development to create a novel therapeutic paradigm – the systematic enhancement of the biological and therapeutic properties of cells ex vivo. This allows for the creation of a precise, scalable and cost effective approach to maximize the safety and effectiveness of cell-based therapies.
While our competitors are using genetic modification and pharmacological modulation to alter and enhance the biological properties of cells, we are taking A Physics Approach to Biology™ in the use of bioelectronics to create ex vivo modulated cells with enhanced biological and therapeutic properties. Using our Cytotronics™ platform, we are able to create cells that express higher levels of key genes related to stem cell maintenance, cell growth, cell homing and engraftment. Cytotronic™ expansion of peripheral blood stem cells resulted in an over 80-fold expansion of CD34+ cells in as few as 6 days.
Our Cytotronic™ platform was shown to be able to maintain normal human neural progenitor (NHNP) cells in long term culture (180 days), undifferentiated with the ability to be cryogenically preserved then subsequently reintroduced into culture with stem and progenitor markers still intact. NHNP cells that were expanded using our technology were then shown to not be tumorigenic when introduced into nude (athymic) mice for 85 days. Multi-color Fluorescence In Situ Hybridization (mFISH) showed that there was no chromosomal damage to cells subjected to Time-Varying Electromagnetic Fields (TVEMF).
Perivascular Cell Therapy Created Using Cytotronics™
Each year, an estimated 60,000 patients with leukemia and lymphoma need bone marrow transplantation. However, only 25,000 of those patients actually receive a transplant, primarily because the other 35,000 patients are unable to find a fully matched bone marrow donor.
Umbilical cord blood from newborn children is an excellent source of hematopoietic stem cells for stem cell transplants because their immune system is still immature and the stem cells have a lower probability of inducing an adverse immune response in patients. Furthermore, a perfect immunological match between donor and recipient is not necessary, unlike in bone marrow transplants.
However, in most cases a unit of umbilical cord blood contains too few stem cells to treat an adult patient and its use is confined above all to the treatment of children. Numerous patients have better matched cord blood products available (5/6 or 6/6 HLA match), however those products have low cell doses and are not suitable for use in adult patients. This is one of the reasons why less than 3 percent of cord blood collected in the United States is ever used. Low volume cord blood units present the opportunity to expand and/or enhance these unused cord blood units for the widespread use of hematopoietic stem cells in regenerative medicine.
Off-The-Shelf Therapeutic
Our Perivascular Cell Therapy is created using immunologically privileged and immune-modulating stem cells from a portion of the human umbilical cord and co-cultured with adipose-derived stem cells along with cord blood cells to create a perivascular cell mixture that can be used to treat malignant and non-malignant hematological disorders.
Endonovo’s cell therapy is an off-the-shelf therapeutic that can be stored indefinitely in a low temperature freeze without requiring cryopreservation. Our technologies are particularly suited to expand the use and effectiveness of low-volume cord blood units.
More In Vivo-Like Stem Cells
Our off-the-shelf therapeutic is created in a three-dimensional bioreactor using our proprietary Cytotronics™ platform to further expand and enhance the biological properties of the stem cells within the perivascular cell mixture. Our use of a perivascular co-culture in a three-dimensional bioreactor is meant to mimic the way that blood-forming stem cells renew and reside in the body. This simulated stem cell niche allows for the expansion of long-term self-renewing stem cells. Researchers had previously identified endothelial and perivascular cells as the cells that were functionally responsible for the maintenance of blood-forming stem cells (HSCs) in the body. Our technologies provide a method for the expansion of HSCs in an environment that resembles their native stem cell niche..
